Market capitalization | $1.15m |
Enterprise Value | $-4.50m |
EV/Sales (TTM) EV/Sales | -450.00 |
P/S ratio (TTM) P/S ratio | 115.00 |
Revenue growth (TTM) Revenue growth | -97.40% |
Revenue (TTM) Revenue | $10.00k |
EBIT (operating result TTM) EBIT | $-29.42m |
Cash position | $7.19m |
EPS (TTM) EPS | $-9.85 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Advaxis, Inc.:
1 Analyst has issued a forecast Advaxis, Inc.:
Jun '23 |
+/-
%
|
||
Revenue | 0.01 0.01 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -29 -29 |
-
|
Net Profit | -28 -28 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.
Head office | United States |
CEO | Ken Berlin |
Founded | 2017 |
Website | www.ayalapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.